Undetected Multidrug-Resistant Tuberculosis Amplified by First-line Therapy in Mixed Infection
Suzanne M. Hingley-Wilson1 , Rosalyn Casey1, David Connell, Samuel Bremang, Jason T. Evans, Peter M. Hawkey, Grace E. Smith, Annette Jepson, Stuart Philip, Onn Min Kon, and Ajit Lalvani
Author affiliations: Imperial College London, London, UK (S.M. Hingley-Wilson, R. Casey, D. Connell, S. Bremang, A. Lalvani); Heart of England National Health Service Foundation Trust, Birmingham, UK (J.T. Evans, P.M. Hawkey, G.E. Smith); School of Infection and Immunity, University of Birmingham, Birmingham (P.M. Hawkey); Imperial College National Health Service HealthcareTrust, London (A. Jepson, S. Philip, O.M. Kon); 1Current affiliation: University of Surrey, Guildford, UK.
Figure 1. . Mycobacterium tuberculosis co-culture competition experiment in a study of the amplification of multidrug resistance induced by first-line treatment of a mixed M. tuberculosis infection. The results suggest competitive advantages in vitro, which may account for patient strain phenotype in vivo. S, drug sensitive; R, drug resistant; OADC, oleic acid, albumin, dextrose, catalase growth supplement; OD600, optical density read at 600 nm; −INH, without isoniazid; +INH, with INH; MIRU-VNTR, mycobacterial interspersed repetitive unit–variable number tandem repeat; CFU, colony-forming units.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.